Clinical Trials Browser

Withdrawn × Multiple Myeloma × fludarabine × Clear all

Multiple Myeloma

NCT05950113 2024-05-01

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Withdrawn

Plasma cell

Multiple Myeloma

NCT05513612 2023-03-01

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Phase 1 Withdrawn

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02118311 2017-12-02

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Phase 2 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

NCT02447055 2016-07-12

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma

Phase EARLY_PHASE1 Withdrawn

Plasma cell

Multiple Myeloma

Clinical Trials

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma